Altimmune has received a potential five-year, $120.2 million contract from the Biomedical Advanced Research and Development Authority to conduct clinical
The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31
The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five
